Value of drug level testing and antibody assays in optimising biological therapy
暂无分享,去创建一个
[1] Theo Rispens,et al. Immunogenicity of biological therapeutics: from assay to patient , 2012, Current opinion in rheumatology.
[2] S. Vermeire,et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. , 2010, Journal of Crohn's & colitis.
[3] P. Rutgeerts,et al. Anti-TNF induced skin manifestations in IBD patients : characterization and search for predisposing factors , 2011 .
[4] G Van Assche,et al. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment , 2011, Gut.
[5] An Carbonez,et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.
[6] W. Sandborn,et al. Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.
[7] M. Silverberg,et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.
[8] J. Gisbert,et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response , 2012, Inflammatory bowel diseases.
[9] P. Goupille,et al. Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study , 2011, Therapeutic drug monitoring.
[10] K. Bendtzen,et al. Clinical implications of variations in anti‐infliximab antibody levels in patients with inflammatory bowel disease , 2012, Inflammatory bowel diseases.
[11] P. Rutgeerts,et al. 405 High Infliximab Trough Levels are Associated With Mucosal Healing in Crohn's Disease , 2010 .
[12] K. Van Steen,et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.
[13] Ann Gils,et al. OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial , 2012 .
[14] M. Silverberg,et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] L. Croner,et al. 565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD) , 2012 .